[
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-1",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#definitiongeneral368886",
    "clean_content": "Definition / general\n\n* Poorly differentiated, high grade, malignant epithelial neoplasm with neuroendocrine differentiation* Poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs) are divided into small cell type (SC PanNEC) and large cell type (LC PanNEC)"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-2",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#essentialfeatures368887",
    "clean_content": "Essential features\n\n* Poorly differentiated neuroendocrine carcinomas represent a distinct entity from well differentiated (G1, G2, G3) neuroendocrine tumors ([Am J Surg Pathol 2012;36:173](22251937))* By morphology, PanNECs can be divided into small cell or large cell subtypes* At the immunohistochemical level, the expression of neuroendocrine markers can be partial or weak (chromogranin A expression can even be absent)* Tumor necrosis and high grade cytology* Ki67 proliferation index > 20% (usually uniform and > 60%) ([Ann Oncol 2013;24:152](22967994))\n          + Mitotic rate of > 20 mitoses/2 mm2"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-3",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#terminology368888",
    "clean_content": "Terminology\n\n* Neuroendocrine carcinoma refers to poorly differentiated neuroendocrine neoplasms, high grade by definition\n  + Neuroendocrine tumor is now reserved for well differentiated neoplasms with typical pathologic features of neuroendocrine lineage, truly resembling their nonneoplastic counterpart (cells of pancreatic islet), regardless of grade* The current WHO (2019) classification groups pancreatic neuroendocrine neoplasms as follows:\n    1. Pancreatic neuroendocrine microtumor (< 5 mm); previously known as neuroendocrine microadenoma* Well differentiated pancreatic neuroendocrine tumor (WD PanNETs), including nonfunctional PanNETs and functional PanNETs (with clinical evidence of hormone release, such as insulinoma, glucagonoma, gastrinoma, VIPoma)* Poorly differentiated pancreatic neuroendocrine carcinomas (PD PanNECs), including SC PanNECs and LC PanNECs* Mixed neuroendocrine nonneuroendocrine neoplasm (MiNEN)\n      + Mixed neoplasm with a neuroendocrine component combined with a nonneuroendocrine component (typically ductal adenocarcinoma or acinar cell carcinoma)+ Each component must account for ≥ 30% of the tumor cell population and both components should be morphologically recognizable+ Neuroendocrine component may be a tumor (less frequently) or a carcinoma (more frequently)"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-4",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#icdcoding368889",
    "clean_content": "ICD coding\n\n* ICD-O:\n  + [8246/3](https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf#page=68) - neuroendocrine carcinoma, NOS* ICD-11:\n    + [2C10.1 & XH0U20](https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1421495979?data=%7B%22dataType%22%3A%22pc%22%2C%22postcoordinationCodeSet%22%3A%7B%22stemId%22%3A%22http%3A%2F%2Fid.who.int%2Ficd%2Fentity%2F1421495979%22%2C%22axisToValueIds%22%3A%7B%22histopathology%22%3A%5B%7B%22stemId%22%3A%22http%3A%2F%2Fid.who.int%2Ficd%2Fentity%2F311089140%22%7D%5D%7D%7D%7D) - neuroendocrine neoplasms of pancreas & neuroendocrine carcinoma, NOS+ [XH9SY0](https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1294602000) - small cell neuroendocrine carcinoma+ [XH0NL5](https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1278312485) - large cell neuroendocrine carcinoma"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-5",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#epidemiology368890",
    "clean_content": "Epidemiology\n\n* Rare (accounting for < 1% of all pancreatic tumors and no more than 2 - 3% of pancreatic neuroendocrine neoplasms)* Mean patient age is 59 years (patients are usually aged 50 - 60 years but can occur in younger patients as well)* M:F = 1.4:1* Large cell variant is more commonly encountered (60%) ([Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-6",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#sites368891",
    "clean_content": "Sites\n\n* Pancreatic gland (head, neck, body, tail)* Head of the pancreas is the most common site ([Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-7",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology / etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#pathophysiologyetiology368892",
    "clean_content": "Pathophysiology / etiology\n\n* Largely unknown* Tobacco smoking"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-8",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagrams / tables",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#diagramstables368893",
    "clean_content": "Diagrams / tables\n\nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasneuroendocrinecarcinomadiagram1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398606/figure/F4/)\n\nSurvival curves for  \n well differentiated  \n tumors and   \ncarcinomas"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-9",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#clinicalfeatures368894",
    "clean_content": "Clinical features\n\n* Back pain, jaundice (for PanNECs of pancreatic head) or nonspecific abdominal symptoms, likewise pancreatic ductal adenocarcinomas* Neoplastic syndromes secondary to ectopic hormone production, such as ACTH (rare)* Vast majority (> 90%) of patients present with metastasis at the time of diagnosis ([Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-10",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#diagnosis368895",
    "clean_content": "Diagnosis\n\n* CT scan, MRI and ultrasonography are the preferred imaging modality* FDG PET scans present high standardized uptake value* Somatostatin receptor scintigraphy (SSRS) is often negative (or focal avidity) due to lack of expression of SSTR2 and SSTR5 ([Arch Pathol Lab Med 2020;144:816](32298138))* Diagnosis is by cytology / fine needle biopsy or on surgical specimens ([Am J Surg Pathol 2016;40:1192](27259015))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-11",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#laboratory368896",
    "clean_content": "Laboratory\n\n* Serum hormone activity (such as chromogranin A) is very unusual ([Cancer 1973;31:1523](4350960))* Serum carcinoma associated markers (e.g., CEA, CA19-9, CA125) levels may be elevated ([Am J Surg Pathol 2016;40:1192](27259015))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-12",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#radiologydescription368897",
    "clean_content": "Radiology description\n\n* CT and MRI features: irregular margins and frequent presence of necrotic foci within tumor mass"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-13",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Grading",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#grading368899",
    "clean_content": "Grading\n\n* PanNECs are, by WHO definition high grade, based on Ki67 (MIB1) index > 20% and mitotic rate > 20 mitoses/2 mm2* WD PanNETs are graded from G1 to G3; but G3 PanNETs represent a distinct entity from PanNECs ([Endocr Pathol 2022;33:115](35294740), [Pathologica 2021;113:28](33686308))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-14",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#prognosticfactors368900",
    "clean_content": "Prognostic factors\n\n* Very poor prognosis, compared to WD PanNETs* Metastatic spread is present in most patients at the time of diagnosis* MiNEN including a NEC component show an aggressive behavior: in these tumors, the Ki67 index of the NEC component is the most important prognostic driver ([Endocr Relat Cancer 2018;25:583](29592868))* Even in cases amenable to surgical resection and treated with adjuvant platinum based therapy, the median survival time is very short (< 1 year) and < 25% of patients survive beyond 2 years ([Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-15",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#casereports368901",
    "clean_content": "Case reports\n\n* 27 year old woman with ACTH secreting PanNEC causing Cushing syndrome with pelvic and bilateral ovarian metastases ([Int J Clin Exp Pathol 2015;8:15396](26823901))* 56 year old man presenting with pure, alpha fetoprotein producing PanNEC without another coexisting malignant component, such as adenocarcinoma or hepatoid carcinoma ([BMC Gastroenterol 2015;15:16](25886790))* 65 year old man with SC PanNEC with similar genetic alterations to invasive ductal adenocarcinoma (*KRAS* mutation, altered expressions of *TP53* and *SMAD4 / DPC4*) ([Clin J Gastroenterol 2016;9:261](27262570))* 67 year old woman with cutaneous metastases of a PanNEC with CK20 positivity ([G Ital Dermatol Venereol 2018;153:722](30246953))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-16",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#treatment368902",
    "clean_content": "Treatment\n\n* Surgical resection* Chemotherapy (no established protocol): platinum based regimen ([Pancreas 2021;50:138](33565789))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-17",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#grossdescription368904",
    "clean_content": "Gross description\n\n* Large neoplasms with infiltrative borders* Brownish to whitish color, fleshy or hard consistency and typically with grossly visible necrotic areas ([Endocr Pathol 2022;33:115](35294740), [Pathologica 2021;113:28](33686308))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-18",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#grossimages368905",
    "clean_content": "Gross images\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreasneuroendocrinecarcinomagross1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070453/figure/F1/)\n \n[![](https://www.pathologyoutlines.com/thumb/pancreasneuroendocrinecarcinomagross2.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739953/figure/F3/)\n\nSmall cell carcinoma"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-19",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Frozen section description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#frozensectiondescription368906",
    "clean_content": "Frozen section description\n\n* High grade and hypercellular neoplasm, with necrotic areas* Diagnosis should be postponed to definitive examination after formalin fixation and also supported by ancillary methods ([Endocr Pathol 2022;33:115](35294740), [Pathologica 2021;113:28](33686308))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-20",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#microscopichistologicdescription368908",
    "clean_content": "Microscopic (histologic) description\n\n* Hypercellular neoplasm, with large and irregular nests, infiltrative growth pattern with randomly oriented large vascular structures and desmoplastic type fibrosis* Necrosis with geographic pattern and comedo-like appearance* High rate of cellular turnover (high mitotic rate and high apoptotic rate) ([Front Oncol 2013;3:2](23346552))* SC PanNEC: diffuse sheets of relatively small cells with round or elongated hyperchromatic nuclei, finely granular chromatin and lacking nucleoli; typical feature of nuclear molding (sharing with the pulmonary counterpart) ([Front Oncol 2013;3:2](23346552))* LC PanNEC: nesting / trabecular pattern, with round to polygonal medium to large sized cells, with amphiphilic cytoplasm and atypical nuclei with either coarse chromatin or conspicuous nucleoli; the nuclear to cytoplasmic (N/C) ratio of LCNECs is lower than that of SCNECs"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-21",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#microscopichistologicimages368909",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Claudio Luchini, M.D., Ph.D. and AFIP images  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini01.jpg)\n\nGeneral morphological appearance\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini02.jpg)\n\nTumor necrosis\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini03.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini03.jpg)\n\nLarge cell PanNEC\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini04.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini04.jpg)\n\nSmall cell PanNEC\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini05.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini05.jpg)\n\nNodal metastasis of PanNEC\n\n  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini06.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini06.jpg)\n\nSynaptophysin positivity\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini07.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini07.jpg)\n\nChromogranin A positivity\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini08.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini08.jpg)\n\nTypical p53 expression\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini09.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaLuchini09.jpg)\n\nRb loss\n\n  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP1.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP1.jpg)\n\nFocal necrosis\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2A.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2A.jpg)\n\nIntense immunostaining for NSE\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2B.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2B.jpg)\n\nSolid diffuse pattern\n\n[![](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2C.jpg)](https://www.pathologyoutlines.com/imgau/pancreasneuroendocrinecarcinomaAFIP2C.jpg)\n\nScattered somatostatin immunoreactive cells"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-22",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#cytologydescription368911",
    "clean_content": "Cytology description\n\n* Scant cytoplasm, slightly granular and high N/C ratio* SC PanNEC: small cells with large nuclei, nuclear molding, finely speckled and dark chromatin with inconspicuous nucleoli, prominent background degeneration and typical crush artifact with nuclear streaming ([Am J Surg Pathol 2012;36:173](22251937))* LC PanNEC: large undifferentiated cells with bizarre forms or syncytial aggregates, irregular overlapping nuclei with prominent nucleoli, vesicular chromatin and abundant cytoplasm (delicate, dense or granular) ([Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-23",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#cytologyimages368912",
    "clean_content": "Cytology images\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreasneuroendocrinecarcinomacyto01.jpg)](https://journals.lww.com/cancerjournal/_layouts/15/oaks.journals/ImageView.aspx?k=cancerjournal:2015:11004:00011&i=F1-11&year=2015&issue=11004&article=00011&type=Fulltext)\n\nOverlapping pancreatic cells"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-24",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#positivestains368915",
    "clean_content": "Positive stains\n\n* [Cytokeratins](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) ([CK8](https://www.pathologyoutlines.com/topic/stainsck8.html) / [CK18](https://www.pathologyoutlines.com/topic/stainsck18.html), [CK AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html))* [Synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html): usually positive, may be rarely weak or focal ([Am J Surg Pathol 2012;36:173](22251937))* [Chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html): usually positive or weakly positive; can be also almost absent; SC PanNEC can also show a paranuclear dot-like immunoreactivity ([Endocr Pathol 2018;29:150](29520563))* [CD56](https://www.pathologyoutlines.com/topic/cdmarkerscd56.html), [neuron specific enolase (NSE)](https://www.pathologyoutlines.com/topic/stainsNSE.html), [protein gene product 9.5 (PGP9.5)](https://www.pathologyoutlines.com/topic/PGP95.html) / [ubiquitin C terminal hydrolase 1 protein (UCHL1)](https://www.pathologyoutlines.com/topic/cdmarkerscd40.html#cd45ro): general neuroendocrine markers, less specific, limited utility* [Insulinoma associated protein 1 (INSM1)](https://www.pathologyoutlines.com/topic/stainsinsm1.html) has emerged as an additional general neuroendocrine marker ([Am J Clin Pathol 2015;144:579](26386079))* **Achaete-scute homolog 1 (ASH1)** ([Hum Pathol 2013;44:1391](23375646))* [p53](https://www.pathologyoutlines.com/topic/stainsp53.html): abnormal expression pattern / nuclear accumulation ([Pathologica 2021;113:28](33686308))* Useful (but neither ideal nor absolute) panel for determining pancreatic origin is **PDX1**+, **ISL1**+, [PAX8](https://www.pathologyoutlines.com/topic/stainspax8.html)+, [CDX2](https://www.pathologyoutlines.com/topic/stainsCDX2.html)+, [TTF1](https://www.pathologyoutlines.com/topic/stainsTTF1.html)- ([Pathologica 2021;113:28](33686308))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-25",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#negativestains368916",
    "clean_content": "Negative stains\n\n* [Rb](https://www.pathologyoutlines.com/topic/stainsrb.html) (classic loss of Rb protein) ([Am J Surg Pathol 2012;36:173](22251937))* [SMAD4](https://www.pathologyoutlines.com/topic/stainsdpc4.html) ([Am J Surg Pathol 2016;40:1192](27259015))* [BCL10](https://www.pathologyoutlines.com/topic/stainsBCL10.html) (helping in excluding an acinar cell carcinoma or the presence of a focal acinar differentiation)* [Beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html) (no nuclear staining; normal positivity of cell membrane)"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-26",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#molecularcytogeneticsdescription368919",
    "clean_content": "Molecular / cytogenetics description\n\n* Alterations of *TP53* and *Rb* represent the most typical molecular events in PanNEC ([Cancer Treat Rev 2017;56:28](28456055), [Cancer Discov 2022;12:692](34880079))* *KRAS* is also mutated in a significant proportion of cases (up to 30%) ([Am J Surg Pathol 2012;36:173](22251937))* Inactivation of *SMAD4 / DPC4* is also reported (5%) ([Am J Surg Pathol 2012;36:173](22251937))* Microsatellite instability can be present in up to 5 - 8% of cases and should be assessed at the time of diagnosis ([Hum Pathol 2022 Jun 14 [Epub ahead of print]](35714836))"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-27",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#samplepathologyreport368922",
    "clean_content": "Sample pathology report\n\n* Duodenum and pancreatic head, pancreaticoduodenectomy:\n  + Pancreatic neuroendocrine carcinoma, large cell type (see comment)+ Pancreatic head with the presence of a high grade neuroendocrine neoplasm+ Ki67 (MIB1) index 70%; mitotic rate: 50 mitoses/2 mm2+ Presence of tumor necrosis+ The neoplasm infiltrates distal choledochus, adipose tissue and duodenum+ Metastasis in 3/12 lymph nodes+ Surgical margins without tumor involvement+ Comment: The integration of morphology with the immunohistochemical profile (and in particular, CK AE1 / AE3 and CK8 / CK18 positive, synaptophysin positive, chromogranin A weakly positive, TP53: aberrant pattern; Rb: negative) is consistent with the diagnosis of pancreatic neuroendocrine carcinoma."
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-28",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#differentialdiagnosis368923",
    "clean_content": "Differential diagnosis\n\n* [Well differentiated G3 neuroendocrine tumor (WD PanNET)](https://www.pathologyoutlines.com/topic/pancreasWDNET.html):\n  + Nonfunctional PanNETs are identified incidentally and have no symptoms+ PanNETs G3 show avidity on SSRS imaging (Octreoscan and Gallium 68 Dotatate PET / CT)+ Cytology: PanNETs G3 show abundant granular cytoplasm, low N/C and stippled chromatin+ Resection specimens: in PanNETs G3, the G3 component is usually not homogenous and mixed with a lower grade counterpart and the same for [Ki67](https://www.pathologyoutlines.com/topic/stainsKi67.html), which is heterogeneous+ Positive stains: in PanNETs, there are diffuse and strong [chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html) (more specific) and [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) (more sensitive) staining+ Molecular profile: in PanNETs, *TP53* and *Rb* are usually wild type; there are recurrent and mutually exclusive mutations of *DAXX* (death domain associated protein, 25%) and *ATRX* (alpha thalassemia / intellectual disability syndrome X linked, 17.6%), usually wild type in PanNECs ([Science 2011;331:1199](21252315))* **High grade neuroendocrine carcinomas of other sites (pancreatic metastasis)**:\n    + [NKX3.1](https://www.pathologyoutlines.com/topic/stainsnkx3.html)+ in prostate+ [CDX2](https://www.pathologyoutlines.com/topic/stainsCDX2.html)+ / [SATB2](https://www.pathologyoutlines.com/topic/stainsSATB2.html)+ in lower GI tract+ [CDX2](https://www.pathologyoutlines.com/topic/stainsCDX2.html)- / [SATB2](https://www.pathologyoutlines.com/topic/stainsSATB2.html)+ in upper GI tract+ Both pancreas and small bowel primaries can be [PAX8](https://www.pathologyoutlines.com/topic/stainspax8.html)+* **Other pancreatic primaries**:\n      + [Acinar cell carcinoma](https://www.pathologyoutlines.com/topic/pancreasacinar.html):\n        - Positive for [BCL10](https://www.pathologyoutlines.com/topic/stainsbcl10.html) and [trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html)- Usually negative for neuroendocrine markers (scattered positive cells can be observed)+ [Mixed neuroendocrine nonneuroendocrine neoplasms](https://www.pathologyoutlines.com/topic/pancreasmixed.html):\n          - Different components should be identified by morphology and not only by immunohistochemistry+ [Medullary carcinoma](https://www.pathologyoutlines.com/topic/pancreasmedullary.html):\n            - Syncytial growth pattern, intratumor inflammatory cells- Negative for neuroendocrine markers* **Lymphoma**:\n        + Most important markers are [CD3](https://www.pathologyoutlines.com/topic/cdmarkerscd3.html), [CD20](https://www.pathologyoutlines.com/topic/cdmarkerscd20.html), [CD45](https://www.pathologyoutlines.com/topic/cdmarkerscd45.html), [CD79a](https://www.pathologyoutlines.com/topic/cdmarkerscd79a.html)+ Negative for neuroendocrine markers* [Melanoma](https://www.pathologyoutlines.com/topic/skintumormelanocyticmelanoma.html):\n          + Positive for [MART1](https://www.pathologyoutlines.com/topic/stainsMART1.html), [HMB45](https://www.pathologyoutlines.com/topic/stainshmb45.html), [SOX10](https://www.pathologyoutlines.com/topic/stainsSOX10.html)+ Negative for neuroendocrine markers* **Small blue cell tumors** in young adults:\n            + [Desmoplastic small cell tumor](https://www.pathologyoutlines.com/topic/softtissueDSRCT.html) ([Am J Surg Pathol 2004;28:808](15166674)):\n              - Large nests and broad bands of small blue cells, separated by fibrous stroma- Positive stains: [cytokeratins](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) ([AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html) and [CAM5.2](https://www.pathologyoutlines.com/topic/stainsCAM52.html)), [NSE](https://www.pathologyoutlines.com/topic/stainsNSE.html), [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html) and [WT1](https://www.pathologyoutlines.com/topic/stainsWT1.html)- Negative stains: [chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html), [S100](https://www.pathologyoutlines.com/topic/stainsS100.html) and [CD99](https://www.pathologyoutlines.com/topic/cdmarkerscd99.html)+ **Primitive neuroectodermal tumors** ([Am J Surg Pathol 2002;26:1040](12170091)):\n                - Sheets and lobules of small cells with round to oval nuclei, nuclear molding and scant cytoplasm; no Homer-Wright rosettes- Positive stains: [CD99](https://www.pathologyoutlines.com/topic/cdmarkerscd99.html), [cytokeratins](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) ([AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html) and [CAM5.2](https://www.pathologyoutlines.com/topic/stainsCAM52.html)), [NSE](https://www.pathologyoutlines.com/topic/stainsNSE.html), [chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html) or [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) (may be focal or diffuse)- Negative stans: [desmin](https://www.pathologyoutlines.com/topic/stainsdesmin.html), [actin](https://www.pathologyoutlines.com/topic/stainsactin.html), [S100](https://www.pathologyoutlines.com/topic/stainsS100.html) protein, [insulin](https://www.pathologyoutlines.com/topic/insulinstains.html), [glucagon](https://www.pathologyoutlines.com/topic/glucagon.html) or [somatostatin](https://www.pathologyoutlines.com/topic/stainssomatostatin.html)"
  },
  {
    "id": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt-29",
    "source_document": "poorly-differentiated-neuroendocrine-carcinoma_41369_1750166975.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreasneuroendocrinecarcinoma.html#additionalreferences368924",
    "clean_content": "Additional references\n\n* [WHO Classification of Tumours Editorial Board: Digestive System Tumours, 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20)"
  }
]